Health & Biotech
Race Oncology (ASX: RAC) is an ASX-listed clinical stage, global biotechnology company with a dedicated mission to be at the heart of cancer care. Race’s lead asset, bisantrene, is a small molecule anthracene chemotherapeutic. Bisantrene has a unique and rich clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, as well characterised safety profile, and compelling clinical data demonstrating an anti-cancer effect and a lack of cardiotoxicity.
Race is developing bisantrene to address the high unmet need of patients across multiple oncology indications, with an initial focus on metastatic breast cancer (lead indication) and acute myeloid leukaemia (AML), exploring anti-cancer plus cardio-protection in synergy with known standards of care.
As part of its clinical program, Race is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway, following independent research describing bisantrene as the most potent inhibitor of FTO (Fat mass and obesity-associated protein). Dysregulation of RNA (over expression of FTO) has been shown to be a driver of a diverse range of cancers.
Race Oncology is in collaboration with City of Hope, MD Anderson, Sheba City of Health and UNC School of Medicine, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world. Learn more at www.raceoncology.com
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: Race Oncology blows past dosing stage of Phase 1, targets Phase 2
Health & Biotech
ASX Health Stocks: Race and Rhythm make their moves to advance Australian share
Health & Biotech
4D Medical CEO hails launch of world’s first dedicated lung scanner, stock price jumps 30pc
Health & Biotech
Check Up: Gloomy days for biotechs, but there were significant moves on the ASX this week
Health & Biotech
ASX Health Stocks: Race Oncology up 8pc on compelling results for kidney cancer drug Zantrene
Health & Biotech
ASX Health Stocks: Inoviq gets Brazilian patent for the use of BARD1 on lung and colorectal cancer
News
ASX Small Cap Lunch Wrap: Who’s enjoying a mid-week reprieve?
News
2020’s top 100 stocks have gained another 8pc this year on average; but two stocks rose 300pc+ again
Health & Biotech
Here are the ASX heart stocks fighting the number one killer disease in humans
Health & Biotech
ASX Health: Twiggy Forrest’s investment fund takes a stake in this ASX cannabis stock
Health & Biotech
ASX Health Stocks: Pharmaxis jumps 9pc on FDA approval
Director Trades
Directors’ Trades: This week’s list of traders includes three noteworthy fund managers
News
Closing Bell: ASX fails to maintain gains, despite tech gaining 1.7pc
Health & Biotech
ASX Health Stocks: Alterity moves to Phase 2 on cancer drug, Race Oncology secures 6th US patent
News
Closing Bell: ASX has its best day of the year, but not enough to avoid 3pc dip in September
Director Trades
Director Trades: Nearly 50 directors spent more than $100k each on trades this past fortnight
Health & Biotech